Bulimia nervosa and misuse of orlistat: two case reports.
OBJECTIVE
Orlistat (tetrahydrolipstatin) is an intestinal lipase inhibitor that was approved recently for the management and treatment of obesity. This is the first report of the misuse of orlistat in two normal-weight purging bulimia nervosa (BN) patients. METHOD AND RESULTS We report two diagnosed cases of BN in two Spanish women who used orlistat as a purging mechanism after binge episodes. In both cases, the onset of the eating disorder was in adolescence. From the beginning, a restrictive diet, binging, and purging behavior (vomiting and using laxatives) were present. Both patients misused this substance as their only purging mechanism after every binge episode.


CONCLUSIONS
BN patients have used many substances and bizarre behaviors as purging mechanisms. Nevertheless, to the authors' knowledge, these are the first reported cases of orlistat misuse as the only purging mechanism in two BN patients.
Fernández-Aranda
F
F
Department of Psychiatry, University Hospital of Bellvitge, Barcelona, Spain. ffernandez@csub.scs.es
Amor
A
A
Jiménez-Murcia
S
S
Giménez-Martínez
L
L
Turón-Gil
V
V
Vallejo-Ruiloba
J
J
D000328:Adult; D019440:Anti-Obesity Agents / Q000627:therapeutic use*; D002032:Bulimia / Q000188:drug therapy*; D005260:Female; D006801:Humans; D007783:Lactones / Q000627:therapeutic use*; D000077403:Orlistat; D012646:Self Administration / Q000706:statistics & numerical data
D019440:Anti-Obesity Agents; D007783:Lactones; D000077403:Orlistat